What is the appropriate dose of polyethylene glycol 3350 (Miralax) for a 3‑year‑old child weighing 32 lb (≈14.5 kg) with constipation?

Dosing Recommendation for Miralax in a 3-Year-Old

For a 3-year-old child weighing 32 lbs (14.5 kg) with constipation, start with approximately 6 grams of polyethylene glycol 3350 (Miralax) once daily, mixed in 4-6 ounces of liquid, and titrate up to 12 grams daily as needed to achieve 2 soft stools per day.

Weight-Based Dosing Approach

The optimal maintenance dose for pediatric constipation is 0.4-0.8 g/kg/day based on high-quality pediatric studies:

• Starting dose: 0.4 g/kg/day = approximately 6 grams daily for this 14.5 kg child 1
• Typical effective range: 0.78-0.84 g/kg/day = approximately 11-12 grams daily 2, 3
• Maximum if needed: Up to 1.0 g/kg/day = approximately 14.5 grams daily

Practical Measurement

Since the standard adult capful is 17 grams 4:

• Start with half a capful (approximately 8.5 grams, close to the 6-gram target)
• Leveled tablespoons contain approximately 10 grams of PEG-3350 5
• Leveled teaspoons contain approximately 3.3 grams 5

For this child, you could prescribe:

• 2 leveled teaspoons once daily (approximately 6.6 grams) as a starting dose
• Titrate up to 3-4 leveled teaspoons (10-13 grams) based on response

Titration Strategy

Adjust the dose every 3 days to achieve the goal of 2 soft stools per day 2. The evidence shows:

• 73-77% of children respond successfully to doses of 0.2-0.8 g/kg/day 1
• Higher doses (0.8 g/kg) are associated with more abdominal pain and fecal incontinence 1
• Starting at 0.4 g/kg provides the best balance of efficacy and tolerability 1

Administration Details

• Mix the powder in 4-8 ounces of any liquid (water, juice, milk) 4
• Give once daily, preferably at the same time each day
• The powder is tasteless and grit-free, improving compliance 6, 2

Expected Response and Duration

• Stool frequency should increase within the first week 2, 1
• Treatment is safe and effective for 6-18 months or longer 7
• No dose adjustment needed for weight gain during long-term use 7

Monitoring for Adverse Effects

Common side effects are mild and dose-related:

• Diarrhea (most common—reduce dose if this occurs) 2, 8
• Bloating and gas (18% of patients) 8
• Nausea (5%) and cramping (5%) 8

Important: These side effects typically resolve with dose reduction and are not reasons to discontinue therapy 2, 7.

Clinical Pitfalls to Avoid

1. Don't underdose: The FDA-approved adult dose of 17 grams daily 9 leads many clinicians to underdose children. Weight-based dosing (0.4-0.8 g/kg) is essential for efficacy.

2. Don't use "heaping" measurements: These create significant dose variability (up to 15 grams per tablespoon) 5. Always level the measuring device.

3. Don't stop too early: Constipation often requires months of treatment. Premature discontinuation leads to relapse 7.

4. Don't ignore persistent constipation: If the child remains constipated despite 0.8-1.0 g/kg/day, reassess for underlying causes rather than continuing to escalate the dose 6.

Safety Profile

PEG 3350 has been extensively studied in children as young as 3 months with excellent safety:

• No clinically significant electrolyte abnormalities 8, 3
• Safe for use in infants and toddlers at similar weight-based doses 3
• No serious adverse events reported in pediatric trials 1, 8, 7

The evidence strongly supports PEG 3350 as first-line therapy for pediatric functional constipation, with a starting dose of 0.4 g/kg/day (approximately 6 grams for this child) titrated to effect 1, 10.